Phase I Amount
$1,390,826
AtlasXomics Inc. is commercializing the next generation of spatial biology tools to help researchers understand the epigenetic mechanisms of disease. The goal of this SBIR grant is to commercialize a product suite of hardware, consumables, and software to spatially interrogate tissue and generate a new layer of data for better understanding gene expression modulation in tissue. The development of novel research tools is critical to address the significant healthcare burden posed by cancer and cardiovascular disease. Epigenetic dysregulation plays a significant role in disease development and response to therapy, but current technologies are inadequate for capturing epigenetic changes in interacting cell populations. AtlasXomics developed and established proof-of-concept performance of the spatial ATAC-seq (Assay for Transposase Accessible Chromatin) assay. In the Phase I, AtlasXomics successfully transferred the academic protocol into a commercial workflow and met industry standards for ATAC-seq quality in mouse and human cancer tissues. The Company introduced the first commercial epigenomics assay to the market in June 2022. In this proposed Phase II, the Company will increase the price performance of the assay to address feedback from customers and prospects: cover a larger area of tissue, increase cellular resolution, and establish a user-friendly, interactive data analysis suite that enables researchers to seamlessly analyze data. The product of this SBIR will be an all-in-one kit that integrates a suite of hardware, consumables, and bioinformatics tools to enable scientists to explore the epigenetic dimension of disease pathology., e.g., characterize tumor and immune cells spatially in the tissue microenvironment. The product will democratize broad adoption of the spatial epigenomics platform because it does not require costly custom equipment and the proposed bioinformatics workflow will also simplify the analysis of the large epigenomics datasets generated by the assay. This product will help scientists to gain biological insight into the spatial epigenetic mechanisms that drive disease progression and therapy response.
Public Health Relevance Statement: Project Narrative Disease often involves cells of multiple types and is accompanied by changes in the composition, structure, and organization of tissues. AtlasXomics is developing a research tool to help researchers understand the spatial modulation of gene expression in tissue, and the epigenetic dysregulation common in cancer and cardiovascular disease.
Project Terms: transcription factor; Basal Transcription Factor; Basal transcription factor genes; General Transcription Factor Gene; General Transcription Factors; Transcription Factor Proto-Oncogene; Transcription factor genes; Genetic Transcription; Gene Transcription; RNA Expression; Transcription; Universities; Transposase; Price; pricing; health care; Healthcare; Data Set; customs; Custom; improved; Site; Area; Phase; biologic; Biological; Germinoma; Training; insight; Disease Progression; Collaborations; Spottings; Genetic; tool; Scientist; Dimensions; Immune; Immunes; Complex; Protocols documentation; Protocol; Location; brain tissue; Closure by clamp; Clampings; interest; Performance; Manuscripts; Structure; novel; Positioning Attribute; Position; Sampling; Proteomics; cardiovascular disorder therapy; cardiovascular disease therapy; Untranslated RNA; Functional RNA; Non-Coding; Non-Coding RNA; Non-translated RNA; Noncoding RNA; Nontranslated RNA; noncoding; cancer therapy; Cancer Treatment; Malignant Neoplasm Therapy; Malignant Neoplasm Treatment; anti-cancer therapy; anticancer therapy; cancer-directed therapy; Bio-Informatics; Bioinformatics; Molecular Interaction; Binding; data processing; computerized data processing; µfluidic; Microfluidics; Skin Lymphoma; Cutaneous Lymphoma; XCL1 gene; ATAC; LPTN; SCM-1; SCM-1a; SCM1; SCYC1; XCL1; Address; Microfluidic Microchips; Microfluidic Device; Microfluidic Lab-On-A-Chip; microfluidic chip; Data; Reproducibility; Resolution; resolutions; Cancer Biology; Epigenetic Process; Epigenetic; Epigenetic Change; Epigenetic Mechanism; epigenetically; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Cardiac; Development; developmental; tumor microenvironment; cancer microenvironment; therapy resistant; resistance to therapy; resistant to therapy; therapeutic resistance; treatment resistance; epigenomics; care burden; cost; data integration; designing; design; next generation; new approaches; novel approaches; novel strategy; novel strategies; Population; innovate; innovative; innovation; resistant; Resistance; transcriptomics; therapeutic effectiveness; user-friendly; commercial application; commercialization; tumor; response to therapy; response to treatment; therapeutic response; therapy response; treatment response; effective treatment; effective therapy; genome scale; genomewide; genome-wide; data reduction; RNA Seq; RNA sequencing; RNAseq; transcriptomic sequencing; transcriptome sequencing; NGS Method; NGS system; next gen sequencing; nextgen sequencing; next generation sequencing; epigenome; ATAC sequencing; ATACseq; ATAC-seq; prognostic tool; Industry Standard; DNA seq; DNAseq; DNA sequencing; patient specific response; responsive patient; patient response; bio-informatics tool; bioinformatics tool; data processing pipeline; data analysis pipeline; computational pipelines; data exploration; immune cell infiltrate; Immune infiltrates; Adoption; Anatomic Sites; Anatomic structures; Anatomy; Bar Codes; barcode; Biological Assay; Assay; Bioassay; Biologic Assays; Biology; Biomedical Research; Biotechnology; Biotech; Brain; Brain Nervous System; Encephalon; Malignant Neoplasms; Cancers; Malignant Tumor; malignancy; neoplasm/cancer; Capital; Cardiovascular Diseases; cardiovascular disorder; Cause of Death; Cell Communication; Cell Interaction; Cell-to-Cell Interaction; Cells; Cell Body; Chromatin; Data Analyses; Data Analysis; data interpretation; Democracy; Disease; Disorder; DNA; Deoxyribonucleic Acid; Elements; Embryo; Embryonic; Equipment; Feedback; Gene Expression; Genome; Goals; Grant; Human; Modern Man; Manuals; Maps; Marketing; melanoma; Malignant Melanoma; Methods; Mus; Mice; Mice Mammals; Murine; Pathology; Phenotype; Play; Publications; Scientific Publication; Research; Research Personnel; Investigators; Researchers; RNA; Non-Polyadenylated RNA; RNA Gene Products; Ribonucleic Acid; Role; social role; Running; Computer software; Software; Standardization; Technology; Time; Tissues; Body Tissues
